AstraZeneca and BMS Receive Award from Major Medical Association
News May 09, 2013
The ACE Philanthropic Award is presented to an industry partner who is a member of the Corporate AACE Partnership (CAP) and has made a charitable contribution to ACE in support of the betterment of endocrine care and public health.
AstraZeneca and Bristol-Myers Squibb formed the diabetes alliance and entered into a collaboration in January 2007 to enable the companies to research, develop and commercialize select investigational drugs for Type 2 Diabetes.
“The AstraZeneca/Bristol-Myers Squibb Diabetes Alliance is honored to be recognized with the ACE Philanthropic Award,” said Shoba Ravichandran, M.D., Group Director, AstraZeneca/Bristol–Myers Squibb Diabetes Alliance. “We share the association’s mission of providing high quality care to patients and supporting clinicians, educators and scientists in their work to overcome the burdens of diabetes and other endocrine related diseases.”
Tiny Kidneys: Building Better Models to Test DrugsNews
A free online kidney atlas built by USC researchers empowers stem cell scientists everywhere to generate more human-like tiny kidneys for testing new drugs and creating renal replacement therapies.READ MORE
Could Alzheimer's Drug Repair Brain Damage After Alcohol Binges?News
A drug used to slow cognitive decline in Alzheimer's disease could offer clues on how drugs might one day be able to reverse brain changes that affect learning and memory in teens and young adults who binge drink.READ MORE
Absolute Antibody and Kerafast Merge Increasing Access to Unique Reagents and Recombinant Antibody TechnologyNews
Absolute Antibody Ltd., and Kerafast Inc., have announced a merger of the two companies. The merger brings together two companies with a shared commitment to improving the selection of research tools available to the scientific community.READ MORE